1-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-ethanone → HCID 58190583, Verbindung

HRID 1892341Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1892341
[F:1][C:2]1[CH:11]=[C:10]2[C:5]([CH:6]=[CH:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[CH2:12][N:13]1[C:21]2[C:16](=[N:17][CH:18]=[C:19]([C:22](=O)[CH3:23])[N:20]=2)[N:15]=[N:14]1.Cl.[NH2:26][O:27][C:28]([CH3:32])([CH3:31])[CH2:29][OH:30]>>[OH:30][CH2:29][C:28]([O:27]/[N:26]=[C:22](/[C:19]1[N:20]=[C:21]2[N:13]([CH2:12][C:3]3[CH:4]=[C:5]4[C:10](=[CH:11][C:2]=3[F:1])[N:9]=[CH:8][CH:7]=[CH:6]4)[N:14]=[N:15][C:16]2=[N:17][CH:18]=1)\[CH3:23])([CH3:32])[CH3:31]

Komponenten

3

Edukt 2

HCID 581905781-[3-(7-Fluoro-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-ethanoneHCID 86647223372105-52-7

Produkt 1

HCID 58190583HCID 58190583, VerbindungAusbeute 97,7 %

Versuchsvorschrift

The title compound (12.0 mg, 89%) was synthesized from 1-[3-(7-fluoro-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-ethanone (15.4) (10.0 mg, 0.03 mmol) and 2-aminooxy-2-methyl-propan-1-ol hydrochloride (8.8 mg, 0.06 mmol) using the same procedure as described in the synthesis of example 15. 1H-NMR (400 MHz, CDCl3) δ ppm 9.41 (s, 1H), 8.94 (d, 1H), 8.18 (d, 1H), 7.94 (d, 1H), 7.83 (s, 1H), 7.46 (dd, 1H), 6.17 (s, 2H), 3.75 (d, 2H), 2.36 (s, 3H), 1.95 (1, 1H), 1.41 (s, 6H). LCMS (method A): [MH]+=410, tR=5.39 min.

Aufarbeitung

  1. customas described in the synthesis of example 15

Quellen und Nachweise

ORD-Eintrag
ord-3e887df302e44799a91eb5f0fb31a99d
Quelldatensatz
uspto-grants-2013_08
Patentnummer
US08507676B2

Notizen zur Reaktion

Wird geladen…